Deltec Asset Management LLC increased its stake in Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 86.4% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 361,804 shares of the company's stock after acquiring an additional 167,680 shares during the quarter. Deltec Asset Management LLC owned 1.25% of Aerovate Therapeutics worth $908,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also bought and sold shares of AVTE. Ieq Capital LLC bought a new position in Aerovate Therapeutics during the fourth quarter worth about $38,000. Corient Private Wealth LLC bought a new stake in Aerovate Therapeutics during the fourth quarter valued at $98,000. JPMorgan Chase & Co. grew its position in Aerovate Therapeutics by 1,021.1% during the fourth quarter. JPMorgan Chase & Co. now owns 67,165 shares of the company's stock worth $178,000 after buying an additional 61,174 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Aerovate Therapeutics by 110.7% in the 4th quarter. Russell Investments Group Ltd. now owns 15,184 shares of the company's stock valued at $40,000 after acquiring an additional 7,977 shares in the last quarter. Finally, Bank of Montreal Can boosted its position in shares of Aerovate Therapeutics by 86.8% during the 4th quarter. Bank of Montreal Can now owns 59,097 shares of the company's stock valued at $157,000 after acquiring an additional 27,453 shares during the last quarter.
Aerovate Therapeutics Stock Performance
AVTE traded down $0.02 on Tuesday, reaching $9.87. The company had a trading volume of 631,787 shares, compared to its average volume of 14,153. Aerovate Therapeutics, Inc. has a 52-week low of $47.60 and a 52-week high of $105.00. The company has a market cap of $286.08 million, a price-to-earnings ratio of -3.30 and a beta of 0.95. The business has a 50 day simple moving average of $25.47 and a 200 day simple moving average of $66.54.
Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) last released its quarterly earnings results on Friday, April 25th. The company reported ($3.15) earnings per share for the quarter, beating analysts' consensus estimates of ($10.50) by $7.35. As a group, equities research analysts predict that Aerovate Therapeutics, Inc. will post -2.64 EPS for the current fiscal year.
Aerovate Therapeutics Dividend Announcement
The business also recently declared a dividend, which was paid on Monday, April 28th. Investors of record on Friday, April 25th were given a dividend of $84.00 per share. The ex-dividend date was Tuesday, April 29th.
About Aerovate Therapeutics
(
Free Report)
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Featured Articles
Before you consider Aerovate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.
While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
